Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers small molecule and recombinant protein drugs for the treatment of liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, and hepatobiliary diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.

Company Data

Name Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Company Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Website https://www.zelgen.com

Primary Exchange

SSE

ISIN CNE100003RP1

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Zelin Sheng

Market Capitalization 29 Mrd.

Country China

Currency CNY

Employees 0,9 T

Address No. 209, Chenfeng Road, 215300 Kunshan

IPO Date 2020-01-23

Ticker Symbols

Name	Symbol
SSE	688266.SS

More Shares

Investors who hold Suzhou Zelgen Biopharmaceuticals Co., Ltd. also have the following shares in their portfolio:

KRAFT HEINZ F. 16/46 Bond

Prospect Commodities Limited Share

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog